- Trials with a EudraCT protocol (131)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
131 result(s) found for: T-lymphocytes.
Displaying page 1 of 7.
EudraCT Number: 2021-000417-16 | Sponsor Protocol Number: Uni-Köln-4480 | Start Date*: 2021-10-20 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: A Phase I / randomized Phase II trial to analyse safety and efficacy of human SARS-CoV 2 specific T lymphocyte transfer in patients with COVID-19 in need of treatment or at risk of severe COVID-19 | |||||||||||||
Medical condition: Patients who are tested positive for SARS-CoV-2 by PCR from upper or lower respiratory sites and are at increased risk for developing critical disease presenting with moderate disease -WHO ordinal ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003270-32 | Sponsor Protocol Number: IISR-2014-100922 | Start Date*: 2016-02-09 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | |||||||||||||
Full Title: Identification of circulating and tissutal T cell subsets to predict clinical and endoscopical response to Entyvio® (vedolizumab) in patients with Ulcerative Colitis (UC) and Crohn’s disease (CD) | |||||||||||||
Medical condition: Ulcerative colitis (UC) and Crohn disease (CD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005582-13 | Sponsor Protocol Number: CHUBX2020/26 | Start Date*: 2021-03-03 |
Sponsor Name:CHU de Bordeaux | ||
Full Title: Prospective pilot study evaluating a therapeutic synergy between the infusion of CMV-specific immunoglobulins and the level before transplantation of negative gamma delta Vdelta 2 T lymphocytes exp... | ||
Medical condition: CMV infection in transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003997-74 | Sponsor Protocol Number: 2005-1 | Start Date*: 2006-02-09 |
Sponsor Name:Rigshospitalet | ||
Full Title: Depletion of regulatory T-lymphocytes by intratumoral injection of antibodies. | ||
Medical condition: Cancer with metastasis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001263-70 | Sponsor Protocol Number: IIBSP-CAR-2019-30 | Start Date*: 2020-03-03 |
Sponsor Name:Institut de Recerca H. de la Santa Creu i Sant Pau | ||
Full Title: Immunotherapy with differential, adult, autologous, peripheral blood cells, expanded and transduced (genetically modified) using a lentiviral vector to express a chimeric receptor with anti-CD30 sp... | ||
Medical condition: Classic Hodgkin lymphoma and T-cell lymphoma with CD30 expression | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005150-28 | Sponsor Protocol Number: PTC:VS-TC | Start Date*: 2022-07-25 | |||||||||||
Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI | |||||||||||||
Full Title: Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation(HSCT) | |||||||||||||
Medical condition: Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022293-14 | Sponsor Protocol Number: ANRS146OPTIMAL | Start Date*: 2012-08-22 |
Sponsor Name:Inserm-ANRS | ||
Full Title: Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defi... | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002876-26 | Sponsor Protocol Number: 2017-002876-26 | Start Date*: 2018-10-19 | |||||||||||
Sponsor Name:South Tees Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Telomerase ACTivator to reverse Immunosenescence in Acute Coronary Syndrome: a double-blind, phase II, pilot randomised controlled trial (TACTIC) | |||||||||||||
Medical condition: Immunosenescence in patients who have had an acute coronary syndrome diagnosed within the last 6 months. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000106-37 | Sponsor Protocol Number: 37.07.-92906 | Start Date*: 2008-08-28 | |||||||||||
Sponsor Name:Klinik für Dermatologie und Allergologie der RUB, St. Josef Hospital | |||||||||||||
Full Title: Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris | |||||||||||||
Medical condition: Psoriasis vulgaris (Plaque-Typ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006126-10 | Sponsor Protocol Number: Efalizumab in CTCL | Start Date*: 2008-11-27 |
Sponsor Name:Charité - University Hospital Berlin | ||
Full Title: pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma | ||
Medical condition: The cutaneous T-cell lymphoma (also known as Sézary syndrome) is a common disorder of proliferated cells with characteristics of maligne t-lymphocytes immigrating from the cutaneous blood vessels t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-002418-38 | Sponsor Protocol Number: LUMC2012-01 | Start Date*: 2012-08-21 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Prophylactic infusion of CD4 positive donor lymphocytes early after T-cell depleted allogeneic stem cell transplantation in patients with an unrelated donor | |||||||||||||
Medical condition: Patients with AML, MDS, ALL, CML in accelerated phase or blastic transformation, CLL, MM or aggressive lymphoma, who underwent a (non) myeloablative allo-SCT with an unrelated donor. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003893-42 | Sponsor Protocol Number: AUTO2-MM1 | Start Date*: 2017-03-28 | ||||||||||||||||
Sponsor Name:Autolus Limited | ||||||||||||||||||
Full Title: A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients with Relapsed or Refractor... | ||||||||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-003238-14 | Sponsor Protocol Number: 104888, 107509 | Start Date*: 2006-09-26 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II/III, observer-blind, multicountry, multicentre, randomized study to demonstrate the superiority in terms of immunogenicity of AS25 adjuvanted influenza vaccine administered in adults age... | ||
Medical condition: Healthy subjects, Immunization against influenza in male and female subjects aged ≥ 50 years. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) NO (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000675-13 | Sponsor Protocol Number: PNS2014-01 | Start Date*: 2016-02-03 |
Sponsor Name:Erasmus University Medical Center | ||
Full Title: Natalizumab (Tysabri®) for the treatment of anti-Hu associated paraneoplastic neurological syndromes | ||
Medical condition: Anti-Hu associated paraneoplastic neurological syndromes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000911-25 | Sponsor Protocol Number: BST-LT-01 | Start Date*: 2019-02-12 | |||||||||||
Sponsor Name:Banc de Sang i Teixits | |||||||||||||
Full Title: A prospective multicenter open, not controlled phase Ib-II clinical trial to assess the safety and immunologic efficacy of virus-specific T lymphocytes from the best donor in receptors of hematopoi... | |||||||||||||
Medical condition: CMV viral infection in an immunocompromised host | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001022-22 | Sponsor Protocol Number: COV-2-STs | Start Date*: 2021-05-14 |
Sponsor Name:Γενικό Νοσοκομείο Θεσσαλονίκης "Γεώργιος Παπανικολάου" | ||
Full Title: Generation of SARS-CoV-2-specific T lymphocytes from recovered donors and administration to high-risk COVID-19 patients | ||
Medical condition: COVID-19 high-risk patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004725-23 | Sponsor Protocol Number: Penta-STs-001 | Start Date*: 2021-10-05 |
Sponsor Name:Γενικό Νοσοκομείο Θεσσαλονίκης "Γεώργιος Παπανικολάου" | ||
Full Title: Administration of rapidly generated multipathogen-specific T-Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus fumigatus infections post Allogeneic Stem Cell Transplant | ||
Medical condition: Hematopoietic stem cell transplant (HSCT) recipients with AdV, EBV, CMV, BKV or Aspergillus fumigatus (AF) infection/ reactivation or with active disease. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002556-39 | Sponsor Protocol Number: 2020/0422/HP | Start Date*: 2022-11-28 |
Sponsor Name:DRCI - CHU de Rouen | ||
Full Title: Efficacy of a preventive strategy for immuno-guided cytomegalovirus infection compared to a universal prophylactic strategy in renal transplant recipients | ||
Medical condition: Patients receiving a kidney transplant (1 to 12 days post-transplant) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006146-34 | Sponsor Protocol Number: 100505 | Start Date*: 2008-04-30 |
Sponsor Name:Stage Pharmaceuticals GmbH | ||
Full Title: Adoptive Immunotherapy of chemotherapy refractory CMV infections using Streptamer-isolated T cells after allogeneic bone marrow or peripheral blood stem cell transplantation: a phase I/II trial | ||
Medical condition: -chronic persistent CMV infection after allogeneic bone marrow or peripheral blood stem cell transplantation, refractory to antiviral chemotherapy | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003409-23 | Sponsor Protocol Number: MERMAID1 | Start Date*: 2023-12-12 | |||||||||||
Sponsor Name:Medical University of Warsaw | |||||||||||||
Full Title: Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia. with resistance, relapse or detectable measurable residual disease. Phase I/I... | |||||||||||||
Medical condition: B-cell acute lymphoblastic leukemia. with resistance, relapse or detectable measurable residual disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
